In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


University of Arkansas

Latest From University of Arkansas

Oncology Disruption Demands Strategic Transformation

The rapidly accelerating complexity of oncology drug development demands a new way of doing business. To succeed in this new landscape, biopharma companies must transform their portfolios and partnerships, and shift toward more dynamic business and operating models and decision-making processes.

BioPharmaceutical Business Strategies

NIH To Fund Three Robotic Projects To Improve Health And Quality Of Life

The National Institutes of Health (NIH) plans to provide $2.2 million in funding over the next five years for the development of three innovative "co-robot" projects: an affordable hand-worn device to help the visually impaired grasp objects, a smart-walker to increase mobility in the elderly and a social-robot companion for children. The hand-worn device, which can detect a small object and help the blind user maintain alignment with the object while approaching it, has a global market potential of nearly $20 billion.

Medical Device Innovation

Clinical Update (10/2007)

Brief summaries of recent clinical developments in the device industry, including heart muscle cells that power simple machines, nanoparticles that may aid in early disease detection, an advanced nanowire device coating, new insights into hearing, and a new biomarker for prostate cancer.
Medical Device

Celgene Backs into Biotech

A marketed product, a second in registration, and $300 million cash enabled Celgene to acquire a biotech capability and expand beyond its roots as a chiral chemistry company. But it took 15 years to get there. Formed as a bioremediation and chiral chemistry company in 1986, it struggled with those businesses. However, its chemical mentality led to in-licensing rights to thalidomide, which subsequently demonstrated activity in cancer. It reached profitability last year on sales of that drug, and with a chiral form of Ritalin pending approval, it finally had the resources to backfill a biology capability. Its purchase of Signal Pharmaceuticals gives it that and is its solution to the late-stage model problem of how to move beyond initial products and leverage a commercial infrastructure.
BioPharmaceutical Strategy
See All